Drugplain

Meclizine Hydrochloride 25 mg/1

Meclizine Hydrochloride · TABLET · American Health Packaging

10 Recalls on Record
Plain English

Meclizine Hydrochloride is a tablet containing meclizine hydrochloride at 25 mg/1, taken oral. Manufactured by American Health Packaging.

Key Facts

Brand Name
Meclizine Hydrochloride
Generic Name
Meclizine Hydrochloride
NDC Code (Product)
60687-730
Manufacturer
American Health Packaging
Strength
25 mg/1
Dosage Form
TABLET
Route
ORAL
Marketing Status
Application #
ANDA201451
Marketing Start
04/20/2023

Recall History

10 Recalls on Record
Class III10/01/2019

Sato Pharmaceutical Inc.

Subpotent Drug

TerminatedVoluntary: Firm initiated
Class III10/26/2015

Par Pharmaceutical Inc.

Failed Impurities/Degradation Specifications: Out of specification for impurities.

TerminatedVoluntary: Firm initiated
Class I03/08/2022

Jubilant Cadista Pharmaceuticals, Inc.

Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles are Meclizine Hydrochloride

TerminatedVoluntary: Firm initiated
Class III11/25/2015

Golden State Medical Supply Inc.

Failed Impurities/Degradation Specifications: Out of specification for impurities.

TerminatedVoluntary: Firm initiated
Class III10/01/2019

Sato Pharmaceutical Inc.

Subpotent Drug

TerminatedVoluntary: Firm initiated
Class III11/25/2015

Golden State Medical Supply Inc.

Failed Impurities/Degradation Specifications: Out of specification for impurities.

TerminatedVoluntary: Firm initiated
Class III10/01/2019

Sato Pharmaceutical Inc.

Subpotent Drug

TerminatedVoluntary: Firm initiated
Class III10/26/2015

Par Pharmaceutical Inc.

Failed Impurities/Degradation Specifications: Out of specification for impurities.

TerminatedVoluntary: Firm initiated
Class III10/01/2019

Sato Pharmaceutical Inc.

Subpotent Drug

TerminatedVoluntary: Firm initiated
Class II03/16/2026

Amerisource Health Services LLC

Failed tablet specifications.

OngoingVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

dizziness1,598 reports
nausea1,376 reports
fatigue1,329 reports
headache1,030 reports
diarrhoea1,015 reports
pain994 reports
fall982 reports
dyspnoea862 reports
chronic kidney disease839 reports
asthenia811 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 ).

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Recommended dosage: 25 mg to 100 mg daily, in divided doses ( 2.1 ). Tablets: Swallow whole ( 2.2 ). 2.1 Recommended Dosage The recommended dosage is 25 mg to 100 mg daily administered orally, in divided doses, depending upon clinical response. 2.2 Administration Instructions Tablets: Meclizine hydrochloride tablets must be swallowed whole.

Contraindications

4 CONTRAINDICATIONS Meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see Adverse Reactions (6) and Description (11) ]. Meclizine hydrochloride tablets are contraindicated in patients with hypersensitivity to meclizine or any of the inactive ingredients ( 4 ).

Drug Interactions

7 DRUG INTERACTIONS Coadministration of meclizine hydrochloride tablets with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride tablets and CYP2D6 inhibitors ( 7.2 ). 7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride tablets are administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1) ] . 7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore, there is a possibility for a drug interaction between meclizine hydrochloride tablets and CYP2D6 inhibitors. Therefore, monitor for adverse reactions and clinical effect accordingly.

Adverse Reactions

6 ADVERSE REACTIONS The following adverse reactions associated with the use of meclizine hydrochloride were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported. Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Frequently Asked Questions

What is Meclizine Hydrochloride used for?

Meclizine Hydrochloride contains Meclizine Hydrochloride. It is a tablet taken oral. Consult your doctor for specific uses.

Is Meclizine Hydrochloride a controlled substance?

Meclizine Hydrochloride is not classified as a controlled substance by the DEA.

What is the generic name for Meclizine Hydrochloride?

The generic name for Meclizine Hydrochloride is Meclizine Hydrochloride. There are 4 other brand versions of Meclizine Hydrochloride.

What is the NDC code for Meclizine Hydrochloride 25 mg/1?

The NDC (National Drug Code) for Meclizine Hydrochloride 25 mg/1 is 60687-730, listed by American Health Packaging.